

1 **Novel Structural Features of Human Norovirus Capsid**

2

3 Jessica Devant<sup>1,2</sup>, Götz Hofhaus<sup>3</sup>, and Grant S. Hansman<sup>1,2,#</sup>

4

5 <sup>1</sup>Schaller Research Group at the University of Heidelberg and the DKFZ, Heidelberg,  
6 Germany

7 <sup>2</sup>Department of Infectious Diseases, Virology, University of Heidelberg, Heidelberg,  
8 Germany

9 <sup>3</sup>Bioquant, CellNetWorks, University of Heidelberg, Heidelberg, Germany

10

11 SHORT TITLE: Cryo-EM structure of GII.4 norovirus VLPs

12

13 <sup>#</sup>Corresponding author

14 Grant S. Hansman: CHS Foundation, University of Heidelberg, and German Cancer  
15 Research Center, Heidelberg, Germany. Email: g.hansman@dkfz.de

16 ABSTRACT

17 Human noroviruses are a major cause of gastroenteritis, yet there are still no vaccines  
18 or antivirals available. Nevertheless, a number of vaccine candidates that are currently  
19 in clinical trials are composed of norovirus virus-like particles (VLPs). These VLPs  
20 are recognized as morphologically and antigenically similar to norovirus virions. An  
21 X-ray crystal structure of the prototype (GI.1) VLPs showed that the norovirus capsid  
22 has a T=3 icosahedral symmetry and is composed of 180 copies of the major capsid  
23 protein (VP1) that folds into three quasi-equivalent subunits (A, B, and C). In this  
24 study, we determined the cryo-EM structure of VLPs for two GII.4 noroviruses that  
25 were detected in 1974 and 2012. We showed that these VLPs had a T=4 symmetry  
26 and were composed of 240 copies of VP1. The VP1 on the T=4 VLPs adapted four  
27 quasi-equivalent subunits (termed A, B, C, and D), which formed two distinct dimers  
28 (A/B and C/D). We found that the T=4 protruding domain was elevated  $\sim 21$  Å off the  
29 capsid shell, which was  $\sim 7$  Å more than the previously determined for the T=3 GII.10  
30 norovirus. Another interesting feature of the T=4 VLPs was a small cavity and flap-  
31 like structure located at the twofold axis. This structural feature was associated with  
32 the shell domain (D subunit) and disrupted the contiguous shell. Altogether, we  
33 showed that the T=4 VLPs had a number of structural similarities and differences  
34 with other noroviruses, but how these structural changes associate with norovirus  
35 virions could be important for vaccine studies.

36 IMPORTANCE

37 The discovery that the GII.4 VLPs (identified in 1974 and 2012, termed CHDC-1974  
38 and NSW-2012, respectively) have a T=4 symmetry is of major significance, since  
39 the NSW-2012 is clinically important and previous structural and biochemical studies  
40 assumed noroviruses have a T=3 symmetry and are composed of 180 copies of VP1.  
41 More importantly, NSW-2012 norovirus shared 96% amino acid identity with a GII.4  
42 vaccine candidate and our data suggests that this vaccine might also have a T=4  
43 symmetry. Although it is not clear if the T=4 VLPs were an artifact of the insect cell  
44 expression system, the T=4 VLP vaccines might not recognize equivalent epitopes on  
45 T=3 virions, which will be important for future neutralization studies. Finally, further  
46 studies with other norovirus genotypes and virions are clearly needed in order to  
47 determine the level of this structural diversity.

## 48 INTRODUCTION

49

50 Human noroviruses are members of the *Caliciviridae* family and are a leading cause  
51 of outbreaks of acute gastroenteritis. The virus has a positive sense, single stranded  
52 RNA genome of ~7.7 kbp. The genome is organized into three open reading frames  
53 (ORFs), where ORF1 encodes nonstructural proteins and ORF2 and ORF3 encode a  
54 major structural protein (termed VP1) and a minor structural protein (termed VP2),  
55 respectively. Noroviruses are genetically diverse and based on VP1 sequences there  
56 are seven genogroups (GI-GVII), where GI, GII, and GIV cause infections in humans  
57 (1, 2). The GI and GII are further subdivided into numerous genotypes, with GII  
58 genotype 4 (GII.4) recognized as the most prevalent and clinically important (3, 4).

59

60 Development of an effective norovirus vaccine or antiviral has been hampered by the  
61 lack of a suitable cell culture system or small animal model. Moreover, the extensive  
62 genetic and antigenic diversity likely hinders vaccine development. Nevertheless,  
63 several vaccine candidates have progressed to phase I and II human clinical trials.  
64 Most vaccines were composed of norovirus GII.4 or GI.1 virus-like particles (VLPs),  
65 which can be produced by expressing VP1 in insect cells. These vaccines were well  
66 tolerated, highly immunogenic, and appeared to be safe, since they did not comprise  
67 of live or attenuated virus. However, limitations of the current vaccine formulations  
68 included mild norovirus like-symptoms, restricted long-term immunity, and limited  
69 cross-protection (5, 6).

70

71 Structural analysis of GI.1 VLPs reveals that VP1 is separated into two distinct  
72 domains: a shell domain (S domain) that encloses the RNA and a protruding domain

73 (P domain) that binds to co-factors, such as histo-blood group antigens (HGBAs) and  
74 bile acids (7-9). A hinge region, which is typically composed of 10-14 amino acids,  
75 also connects the S and P domains. The P domain has a  $\beta$ -barrel fold that is  
76 structurally conserved in the *Caliciviridae* family. Dimerization of the P domains  
77 forms arch shaped protrusions that can be seen using electron microscopy. The P  
78 domain is further subdivided into P1 and P2 subdomain, where P2 subdomain appears  
79 to be an insertion in the P1 subdomain and is the most variable region on the capsid  
80 (7).

81

82 Structural studies have shown that caliciviruses have a common overall organization  
83 of T=3 icosahedral symmetry and are comprised of 180 copies of VP1 (7, 10-13). On  
84 the virus particles, the VP1 forms three quasi-equivalent subunits, termed A, B, and C  
85 (7). The norovirus A and B subunits assemble into 60 dimers (termed A/B) at the  
86 quasi twofold axis, whereas the C subunit assembles into 30 C/C dimers that are  
87 located at the strict icosahedral twofold axis. For the GI.1 VLPs, the A/B dimers have  
88 a bent S domain conformation, whereas the C/C dimers have flat S domain  
89 conformation (7). The conformational differences within these dimers likely  
90 facilitates the curvature of the virus particle to form a closed shell, which is  
91 commonly seen in other T=3 icosahedral viruses (14). Interestingly, smaller norovirus  
92 VLPs (~25 nm in diameter) that are assumed to have a T=1 icosahedral symmetry  
93 were also reported (15, 16); however the structure of these smaller VLPs has not yet  
94 been determined.

95

96 In this study, we determined the cryo-EM structure of VLPs for GII.4 variants that  
97 were identified in 1974 and 2012, termed CHDC-1974 and NSW-2012, respectively

98 (17, 18). We showed that these VLPs had a T=4 icosahedral symmetry and were  
99 composed of 240 copies of VP1. In order to form the T=4 symmetry, VP1 adapted  
100 four quasi-equivalent subunits, termed A, B, C, and D, which subsequently gave rise  
101 to two distinct dimers, termed A/B and C/D. These VLPs consisted of 60 A/B dimers  
102 and 60 C/D dimers, where at the icosahedral 2-fold axis, B, C, and D subunits were  
103 alternating, while the A subunit was located at the fivefold axis. Altogether, our  
104 findings showed that the GII.4 VLPs had structural modifications that might have  
105 important implications for vaccine design.

106 MATERIALS AND METHODS

107

108 **VLP preparation**

109 The NSW-2012 and CHDC-1974 VLPs (Genbank accession numbers JX459908 and  
110 ACT76142, respectively) were expressed in a baculovirus system as previously  
111 described (19-21). Briefly, the bacmid containing the recombinant VP1 gene was  
112 transfected in Sf9 insect cells. After incubation for five days, the culture medium was  
113 centrifuged for 10 min at 3,000 rpm at 4°C. The recovered baculovirus was  
114 subsequently used to infect Hi5 insect cells. After five days post infection, the culture  
115 medium was centrifuged for 10 min at 3,000 rpm at 4°C and then 1 h at 6,500 rpm at  
116 4°C. The VLPs in the supernatant were concentrated by ultracentrifugation at 35,000  
117 rpm for 2 h at 4°C and then further purified using CsCl equilibrium gradient  
118 ultracentrifugation at 35,000 rpm for 18 h at 4°C. To remove the CsCl, the VLPs were  
119 pelleted for 2 h at 40,000 rpm at 4°C and subsequently resuspended in PBS (pH 7.4).

120

121 **Negative stain electron microscopy**

122 The integrity of the VLPs was confirmed by negative stain electron microscopy (EM).  
123 GII.4 virions from stool were also examined using EM (prepared as above expect for  
124 the CsCl equilibrium gradient ultracentrifugation step). Briefly, the VLPs were diluted  
125 1:30 in distilled water and applied to EM grids, whereas the stool sample was diluted  
126 to 10% with PBS, applied to EM grid, washed with water, and then fixed with 4%  
127 glutaraldehyde. The grids were washed with distilled water, stained with 0.75%  
128 uranyl acetate, and the excess uranyl acetate removed with filter paper. EM images  
129 were acquired on a Zeiss 910 electron microscope at 50,000× magnification.

130

131 **Cryo-EM data sample preparation and data collection**

132 UNSW-2012 and CHDC-1974 VLPs (3  $\mu$ l) were applied on freshly glow discharged  
133 Quantifoil holey carbon support films (R1.2/1.3; Quantifoil) and blotted for 18  
134 seconds at 100% humidity at 10°C before been plunged in liquid ethane using an FEI  
135 Mark IV Vitrobot (Thermo Fischer Scientific). Vitrified specimens were imaged on a  
136 Titan Krios operated at 300 keV. NSW-2012 micrographs were acquired with a K2  
137 direct electron detector at 64,000 $\times$  magnification, corresponding to a pixel size of  
138 2.27  $\text{\AA}$ /px, while CHDC-1974 micrographs were collected using a K3 camera with  
139 Latitude S software (Gatan) at 64,000 $\times$  magnification, corresponding to a pixel size of  
140 1.375  $\text{\AA}$ /px.

141

142 **Cryo EM data processing**

143 Images were processed with Relion 2.1 software for NSW-2012 and cryosparc  
144 software for CHDC-1974 (22, 23). Initially, the movies containing 16 frames for  
145 NSW-2012 and 40 frames for CHDC-1974 were motion corrected using motioncor2  
146 software (24) and contrast transfer function (CTF) was performed using ctfind 4.1  
147 software (25). An initial set of 1,000 particles was manually picked for 2D  
148 classification to produce averages suitable as references for automated particle  
149 picking. The autopicked particles were sorted in a 2D classification step and the best  
150 particles were used for calculation of an initial starting model, followed by 3D  
151 classification. A subset of particles that generated the highest resolution was selected  
152 for further refinement. The 3D refinement and post-processing of NSW-2012 from  
153 10,548 particles produced a final map at 7.3- $\text{\AA}$  resolution with I2 symmetry imposed  
154 (0.143 FSC cutoff). For CHDC-1974, a subset of 42,485 particles for refinement  
155 revealed a map of 6.1- $\text{\AA}$  resolution using the 0.143 FSC cutoff. Cryo-EM VLP



156 structures for CHDC-1974 (accession number: EMD-4549) and NSW-2012 (EMD-  
157 4550) were deposited at EMDB.

158

159 **Fitting of the X-ray structures into the density maps**

160 Crystal structures of NSW-2012 P domain (PDB ID: 4OOS) and CHDC-1974 P  
161 domain (5IYN) were fitted into the respective densities using the “fit in map”  
162 command in the UCSF Chimera software (26). Since a high-resolution GII.4 shell  
163 domain was unavailable, the GI.1 Norwalk virus S domain was extracted from the X-  
164 ray crystal structure (1IHM) and fitted into the GII.4 cryo-EM density using UCSF  
165 Chimera software.

## 166 RESULTS AND DISCUSSION

167

168 The purpose of this study was to analyze the GII.4 VLP architecture of NSW-2012  
169 and CHDC-1974 and then relate the findings with known GI.1 and GII.10 VLP  
170 structures. The NSW-2012 VP1 sequence had a single amino acid insertion at position  
171 ~394 (NSW-2012 numbering) compared to CHDC-1974 (Fig. 1). Overall, NSW-2012  
172 and CHDC-1974 shared 89% amino acid identity. Most (45 of 54) amino acid  
173 substitutions were located in the P domain. Negative stain EM images revealed that  
174 these the VLPs exhibited characteristic norovirus morphology (Fig. 2). However, the  
175 diameter of these VLP images was measured to be ~52 nm, which suggested that the  
176 GII.4 VLPs were larger than GII.10 and GI.1 VLPs that had diameters of ~43 nm and  
177 38 nm, respectively.

178

### 179 **Cryo-EM structure of GII.4 NSW-2012 VLPs**

180 The structure of the NSW-2012 VLPs was determined using cryo-EM. The VLPs  
181 were mono-dispersed in vitreous ice and appeared homogenous in size (Fig. 3A).  
182 From the 364 images, 10,548 particles were used for structural reconstruction and  
183 refined to 7.3 Å resolution (Fig. 3B).

184

185 Unexpectedly, NSW-2012 VLPs were discovered to have a T=4 icosahedral  
186 symmetry (Fig. 4). Our data revealed that these VLPs were composed of 240 copies  
187 of VP1, rather than the 180 VP1 copies in GI.1 and GII.10 VLPs. The inner diameter  
188 of NSW-2012 shell was measured as 32 nm, while the outer capsid diameter was 50  
189 nm. Interestingly, this large diameter of the T=4 VLPs corresponded to an inner shell

190 volume of 17,157 nm<sup>3</sup>, which was ~2.6 times the volume of the GII.10 VLPs that had  
191 an inner diameter of 23 nm (13).

192

193 Another interesting structural feature of these NSW-2012 VLPs was a small cavity  
194 and flap-like structure on the contiguous shell (Fig. 5). This feature was associated  
195 with the S domain and found on opposing sides at the twofold axis. Interestingly,  
196 NSW-2012 VLPs were capable of binding HBGAs and norovirus-specific antibodies  
197 (27, 28), which indicated that despite the cavity and flap-like structure these VLPs  
198 were biologically functional.

199

200 Structural analysis of the T=4 VLPs indicated that VP1 adapted four quasi-equivalent  
201 subunits, termed A, B, C, and D. Subsequently, these four subunits gave rise to two  
202 distinct dimers, termed A/B and C/D (Figs. 4 and 6). At the icosahedral twofold axis,  
203 B, C, and D subunits were alternating, while the A subunit was positioned at the  
204 fivefold axis (Fig. 4). Of major importance, the T=4 VLPs comprised of 60 A/B  
205 dimers and 60 C/D dimers, which was distinct from the T=3 GI.1 and GII.10 VLPs  
206 that assembled with 60 A/B and 30 C/C dimers. We also observed that the T=4 A/B  
207 and C/D dimers had a bent conformation at the bottom of the S domain, which was in  
208 contrast to the GI.1 VLPs that consisted of both bent (A/B) and flat (C/C) dimers (7).  
209 Likely, the bent A/B and C/D dimers facilitated the necessary curvature to form  
210 particles with a T=4 symmetry.

211

212 In order to better comprehend how VP1 assembled into the T=4 VLPs, the X-ray  
213 crystal structure of NSW-2012 P domain (4OOS) and GI.1 S domain (1IHM) were  
214 fitted into the VLP density map. We found that the NSW-2012 P domain dimer could

215 be unambiguously positioned into the VLP structure with cross correlation coefficient  
216 of 0.96 (Fig. 7A). This result indicated that the P domain dimers on the T=4 VLPs had  
217 not undergone any major structural modifications. In the case of the S domain, the  
218 GI.1 S domain needed to be manually positioned into the density map. The GI.1 S  
219 domain fitted well into to A/B dimer and the C subunit, while the D subunit needed to  
220 be further repositioned (Fig. 7B). This additional fitting in the D subunit was  
221 necessary in order to occupy the elevated density of the cavity and flap-like regions.

222

223 Unfortunately, it was problematic to fit the hinge region, since the hinge region on the  
224 X-ray crystal structure of NSW-2012 P domain was excluded from the expression  
225 construct and the hinge region on the GI.1 VLPs was flattened (7, 13). Interestingly,  
226 an additional density was also observed between the S domain and the C-terminus of  
227 the P domain on the D subunit (Fig. 8). This connection appeared to stabilize the bent  
228 conformation of the C/D dimer and subsequently the T=4 VLPs. Indeed, the C-  
229 terminus of VP1 on the GI.1 VLPs and the GII.4 P domain were found to be flexible  
230 (7, 28). Interestingly, the C-terminus of VP1 was previously shown to be important  
231 for the size and stability of VLPs (29). Therefore, it is possible that GII.4 VP1  
232 sequence has a remarkable ability to form T=4 VLPs, which could provide an  
233 additional advantage for this genotype.

234

235 Another interesting feature that we observed with the T=4 VLPs was the raised P  
236 domains (Figs. 4 and 8). We found that the T=4 P domain was elevated  $\sim 21$  Å off the  
237 shell, which was higher than the P domains on the GII.10 VLPs, which were raised  
238  $\sim 14$  Å (13). The hinge region in NSW-2012 and GII.10 (13) were both  $\sim 10$  amino  
239 acids and mainly conserved (30). This result suggested that the raised P domains

240 might be a structural feature of GII noroviruses, since the P domains on the GI.1  
241 VLPs were essentially resting on the shell (7).

242

### 243 **Cryo-EM structure of GII.4 CHDC-1974 VLPs**

244 Following these results, we proceeded to determine the cryo-EM structure of the  
245 CHDC-1974 VLPs. The VLPs were mostly mono-dispersed and homogenous in size  
246 (Fig. 9A). From 591 images, 42,485 particles were used for the structural  
247 reconstruction that led to a final resolution of 6.1 Å (Fig. 9B). Remarkably, the  
248 CHDC-1974 VLPs also had a T=4 symmetry (Fig. 10). In fact, the CHDC-1974 VLP  
249 structure closely resembled the structural features of NSW-2012 VLPs.

250

251 We found that CHDC-1974 VLPs were composed of 240 copies of VP1 that formed  
252 the equivalent subunits (A, B, C, and D) and A/B and C/D dimers. The inner diameter  
253 of the shell was 32 nm, whereas the outer diameter of the capsid was 50 nm. The  
254 comparable small cavity and flap-like structures were also present on the CHDC-1974  
255 VLPs (Fig. 11). The CHDC-1974 A/B and C/D dimers showed a similar bend as  
256 NSW-2012 dimers, although slightly less pronounced (Fig. 12). The X-ray crystal  
257 structure of CHDC-1974 P domain (5IYN) was easily fitted into the CHDC-1974  
258 VLP density map (Fig. 13A). The GI.1 S domain also fitted into the A, B, and C  
259 subunits, whereas the GI.1 S domain needed to be again repositioned to occupy the D  
260 subunit (Fig. 13B). Similar to NSW-2012 VLPs, an additional density was observed  
261 between the S and P domains on the D subunit (Fig. 14). Lastly, we found that  
262 CHDC-1974 P domain was also lifted off the shell by ~21 Å (Figs. 10 and 14).

263

264 Overall, these results showed that GII.4 VP1 sequences isolated over three decades  
265 apart remained structurally conserved. This could imply that other GII.4 VP1  
266 sequences also form T=4 VLPs when expressed in insect cells, especially since these  
267 two sequences had only 89% amino acid identity. More importantly, the GII.4  
268 noroviruses have dominated epidemics over the past decade and this structural feature  
269 could represent a selective advantage over other GII genotypes that have a T=3  
270 capsid.

271

### 272 **Structural implications of the T=4 VLPs**

273 Our new discovery of these T=4 GII.4 VLPs could have major implications for  
274 vaccine development. Negative stain EM images of the GII.4c VLPs that are currently  
275 tested in clinical trials showed the typical norovirus morphology (6, 31). However, the  
276 size determination and the structure are not available.

277

278 In general, studies have shown that norovirus-specific antibody titers were raised after  
279 vaccination with VLPs, but the levels of protection were not strongly improved  
280 compared to placebo groups (32). It is tempting to speculate that the GII.4c VLPs  
281 might also form T=4 particles, since the GII.4c and NSW-2012 shared 94% amino  
282 acid identity; most (28 of 31) of the substitutions were located in the P domain; and  
283 the hinge region was identical (Fig. 1). Therefore, this might suggest that the host  
284 could produce neutralizing antibodies against epitopes on the T=4 VLPs that were  
285 not as accessible on T=3 virions and that efficacy is difficult. Indeed, we have  
286 identified several Nanobodies that bind to occluded regions on the T=4 GII.4 VLPs  
287 (30, 33).

288

289 In order to validate if the GII.4 virions actually assemble into T=3 a cryo-EM  
290 structure would be valuable, however norovirus virions are challenging to prepare in  
291 large quantities. Nevertheless, when we compare EM images of GII.4 virions with  
292 these T=4 VLPs we found that the virions were smaller (Fig. 15). Therefore, our  
293 preliminary results suggest that the GII.4 VLPs and virions were different in size and  
294 likely other structural characteristics.

295

## 296 **Summary**

297 At least two important outcomes from this new discovery of these GII.4 T=4 VLPs  
298 will be acknowledged. Firstly, the GII.4 VLPs might influence results from previous  
299 studies that assumed norovirus VLPs were morphologically similar to virions. For  
300 example, the molecular weight of the T=3 and T=4 VLPs would be ~10.5 mDa ( $180 \times$   
301 VP1) and ~14 mDa ( $240 \times$  VP1), respectively. This mass difference would affect  
302 results in mass spectrometry, Biacore, and isothermal titration calorimetry. Secondly,  
303 the VLP vaccines that could be composed of T=4 particles might produce  
304 complicating immune responses. For example, the cavity and flap-like structures on  
305 the T=4 could elicit some antibodies that are not recognized by T=3 virions.  
306 Ultimately, when a patient is immunized with T=4 VLPs, the immune response with  
307 virions could effectively be lower.

308 ACKNOWLEDGEMENTS

309

310 We acknowledge the excellence cluster CellNetworks (Cryo-EM network) of the  
311 University of Heidelberg for cryo-EM data collection, the EM core facility at DKFZ,  
312 and Baden-Württemberg High Performance Cluster (bwHPC). We thank David  
313 Bhella for assistance with structural refinements; Anna Koromyslova for EM images  
314 of GII.4 virions; and Benedikt Wimmer for setting up the cryo-EM software. The  
315 funding for this study was provided by the CHS foundation; the Baden-Württemberg  
316 Stiftung (GLYCAN-BASED ANTIVIRAL AGENTS); Deutsche  
317 Forschungsgemeinschaft (DFG, FOR2327); and the BMBF VIP+ (Federal Ministry of  
318 Education and Research) (NATION, 03VP00912).



319 FIGURE LEGENDS

320

321 **Figure 1. Amino acid sequence alignment of GII.4 VP1.** NSW-2012 (JX459908),  
322 CHDC-1974 (ACT76142), and GII.4c (31) VP1 amino acid sequences were aligned  
323 using ClusterX. The S domain (orange), hinge region (green), P1 subdomain (light  
324 blue), and P2 subdomain (navy) were labeled accordingly. Compared to CHDC-1974,  
325 NSW-2012 and GII.4c VP1 had a single amino acid insertion (arrow) at position 394  
326 (NSW-2012 numbering). The S domain and hinge region were mainly conserved,  
327 whereas most amino acid substitutions were located in the P2 subdomain.

328

329 **Figure 2. EM images and hydrodynamic diameters of NSW-2012 and CHDC-**  
330 **1974 GII.4 VLPs.** Negative stain EM images of the GII.4 VLPs show the  
331 characteristic norovirus morphology (50,000× magnification). The GI.1 West Chester  
332 (AY502016.1) and GII.10 Vietnam026 (AF504671) VLPs are shown as reference (27,  
333 34). The bar represents 100 nm.

334

335 **Figure 3. NSW-2012 cryo-EM data processing.** (A) A representative cryo-EM  
336 micrograph of NSW-2012 VLPs at 64,000× magnification. The scale bar represents  
337 100 nm. (B) Gold standard Fourier shell correlation (FSC) plot of the icosahedral  
338 reconstruction of NSW-2012 indicates a resolution of 7.3 Å.

339

340 **Figure 4. Cryo-EM reconstruction structure of NSW-2012 VLPs.** The left side  
341 shows NSW-2012 VLPs have a T=4 icosahedral symmetry (symmetry axis labeled 2,  
342 3, and 5). These VLPs were composed of 240 copies of VP1. The VP1 adapted four  
343 quasiequivalent conformations (A, B, C, and D) that gave rise to two distinct dimers

344 (A/B and C/D). At the icosahedral twofold axis, the B, C, and D subunits were  
345 alternating, while the A subunit is positioned at the fivefold axis. The right side shows  
346 a cutaway section of these VLPs and indicates that the inner and outer diameters are  
347 32 nm and 50 nm, respectively. The P domains are elevated  $\sim 21$  Å off the S domain.

348

349 **Figure 5. NSW-2012 T=4 VLPs shows several new structural features.** The cavity  
350 and flap-like structures are observed at the twofold axis and are found on opposing  
351 sides. The cavity and flap-like structures are associated with the S domain on the D  
352 subunit.

353

354 **Figure 6. NSW-2012 T=4 VLPs are formed with 60 A/B and 60 C/D VP1 dimers.**  
355 The A/B and C/D dimers show an equivalent bent confirmation on the bottom of the S  
356 domain. An additional connection was observed between the D subunit of the S and P  
357 domain.

358

359 **Figure 7. The X-ray crystal structures of NSW-2012 P domain and GI.1 S**  
360 **domain were fitted into the VLP density map.** (A) The X-ray crystal structure of  
361 NSW-2012 P domain (4OOS, cartoon) could be fitted into the A/B and C/D P domain  
362 dimers, indicating little conformational change. (B) The X-ray crystal structure of the  
363 GI.1 S domain (1IHM, cartoon) fitted into the A/B and C/D S domain dimers.  
364 However, the cavity and flap-like structures on the D subunit suggests a large  
365 conformational change compared to the typical T=3 particles.

366

367 **Figure 8. A close-up view of NSW-2012 C/D dimer.** The fitted X-ray crystal  
368 structures of the GI.1 S domain (cartoon) and the GII.4 P domain (cartoon) into the

369 cryo-EM map shows the how the hinge region connects the S and P domains. Also,  
370 the new connection between the S domain and the C-terminus of the P domain is  
371 shown. The asterisk represents the missing hinge region on the X-ray crystal  
372 structures that connects of the S and P domains for the C subunit (blue) and D subunit  
373 (red).

374

375 **Figure 9. CHDC-1974 cryo-EM data processing.** (A) A representative cryo-EM  
376 micrograph of CHDC-1974 VLPs at 64,000 $\times$  magnification. The scale bar represents  
377 100 nm. (B) FSC plot of the icosahedral reconstruction of CHDC-1974 indicates a  
378 resolution of 6.1  $\text{\AA}$  at 0.143 cutoff.

379

380 **Figure 10. Cryo-EM structure and analysis of CHDC-1974 VLPs.** The image on  
381 the left side shows that CHDC-1974 VLPs has a T=4 icosahedral symmetry and was  
382 composed of 240 copies of VP1. The VP1 adapted four quasiequivalent  
383 conformations (A, B, C, and D) that gave rise to two distinct dimers (A/B and C/D).  
384 At the icosahedral twofold axes, the B, C, and D subunits were alternating, while the  
385 A subunit was located around the fivefold axes. The right side shows a cutaway  
386 section of these VLPs and indicates that the inner and outer diameters are 32 nm and  
387 50 nm, respectively. The P domains are elevated  $\sim 21$   $\text{\AA}$  off the S domain.

388

389 **Figure 11. CHDC-1974 T=4 VLPs shows several new structural features.** The  
390 cavity and flap-like structures are observed at the twofold axis and are found on  
391 opposing sides. The cavity and flap-like structures are associated with the S domain  
392 on the D subunit.

393

394 **Figure 12. CHDC-1974 T=4 VLPs are formed with 60 A/B and 60 C/D VP1**  
395 **dimers.** The A/B and C/D dimers show an equivalent bent confirmation on the  
396 bottom of the S domain. An additional connection was observed between the D  
397 subunit of the S and P domain.

398

399 **Figure 13. The X-ray crystal structures of CHDC-1974 P domain and GI.1 S**  
400 **domain were fitted into the VLP density map.** (A) The X-ray crystal structure of  
401 NSW-2012 P domain (5IYN, cartoon) easily fitted into the A/B and C/D P domain  
402 dimers. (B) The X-ray crystal structure of the GI.1 S domain (1IHM, cartoon) fitted  
403 into the A/B and C/D S domain dimers. However, the cavity and flap-like structures  
404 on the D subunit suggests a large conformational change from typical T=3 particles.

405

406 **Figure 14. A close-up view of CHDC-1974 C/D dimer.** The fitted X-ray crystal  
407 structures of the GI.1 S domain (cartoon) and the GII.4 P domain (cartoon) into the  
408 cryo-EM map shows the how the hinge region connects the S and P domains. Also,  
409 the new connection between the S domain and the C-terminus of the P domain is  
410 shown. The asterisk represents the missing hinge region on the X-ray crystal  
411 structures that connects of the S and P domains for the C subunit (blue) and D subunit  
412 (red).

413

414 **Figure 15. EM images of GII.4 virions.** Negative stain EM images of GII.4 virions  
415 show that the virions exhibit a smaller diameter than GII.4 VLPs expressed in insect  
416 cells.

417 REFERENCES

418

- 419 1. **Pogan R, Schneider C, Reimer R, Hansman G, Uetrecht C.** 2018.  
420 Norovirus-like VP1 particles exhibit isolate dependent stability profiles.  
421 Journal of physics. Condensed matter : an Institute of Physics journal  
422 30:064006.
- 423 2. **Hansman GS, Natori K, Shirato-Horikoshi H, Ogawa S, Oka T,**  
424 **Katayama K, Tanaka T, Miyoshi T, Sakae K, Kobayashi S, Shinohara**  
425 **M, Uchida K, Sakurai N, Shinozaki K, Okada M, Seto Y, Kamata K,**  
426 **Nagata N, Tanaka K, Miyamura T, Takeda N.** 2006. Genetic and  
427 antigenic diversity among noroviruses. The Journal of general virology  
428 87:909-919.
- 429 3. **Donaldson EF, Lindesmith LC, Lobue AD, Baric RS.** 2008. Norovirus  
430 pathogenesis: mechanisms of persistence and immune evasion in human  
431 populations. Immunol Rev 225:190-211.
- 432 4. **Choi SC, Simhadri VR, Tian L, Gil-Krzewska A, Krzewski K, Borrego F,**  
433 **Coligan JE.** 2011. Cutting edge: mouse CD300f (CMRF-35-like molecule-1)  
434 recognizes outer membrane-exposed phosphatidylserine and can  
435 promote phagocytosis. Journal of immunology 187:3483-3487.
- 436 5. **Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira**  
437 **J, Estes MK, Graham DY, Opekun AR, Richardson C, Mendelman PM.**  
438 2011. Norovirus vaccine against experimental human Norwalk Virus  
439 illness. The New England journal of medicine 365:2178-2187.

- 440 6. **Clayton JS, Bolinger HK, Jaykus LA.** 2018. Disinfectant testing against  
441 human norovirus surrogates-What infection preventionists need to know.  
442 *Infection control and hospital epidemiology*:1-2.
- 443 7. **Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK.**  
444 1999. X-ray crystallographic structure of the Norwalk virus capsid.  
445 *Science* **286**:287-290.
- 446 8. **Kilic T, Koromyslova A, Hansman GS.** 2019. Structural Basis for Human  
447 Norovirus Capsid Binding to Bile Acids. *Journal of virology* **93**.
- 448 9. **Tan M, Jiang X.** 2005. The p domain of norovirus capsid protein forms a  
449 subviral particle that binds to histo-blood group antigen receptors.  
450 *Journal of virology* **79**:14017-14030.
- 451 10. **Bhella D, Goodfellow IG.** 2011. The cryo-electron microscopy structure  
452 of feline calicivirus bound to junctional adhesion molecule A at 9-  
453 angstrom resolution reveals receptor-induced flexibility and two distinct  
454 conformational changes in the capsid protein VP1. *Journal of virology*  
455 **85**:11381-11390.
- 456 11. **Chen R, Neill JD, Noel JS, Hutson AM, Glass RI, Estes MK, Prasad BV.**  
457 2004. Inter- and intragenus structural variations in caliciviruses and their  
458 functional implications. *Journal of virology* **78**:6469-6479.
- 459 12. **Kilic T, Koromyslova A, Malak V, Hansman GS.** 2018. Atomic Structure  
460 of the Murine Norovirus Protruding Domain and Soluble CD300lf  
461 Receptor Complex. *Journal of virology* **92**.
- 462 13. **Hansman GS, Taylor DW, McLellan JS, Smith TJ, Georgiev I, Tame JR,**  
463 **Park SY, Yamazaki M, Gondaira F, Miki M, Katayama K, Murata K,**  
464 **Kwong PD.** 2012. Structural basis for broad detection of genogroup II

- 465 noroviruses by a monoclonal antibody that binds to a site occluded in the  
466 viral particle. *Journal of virology* **86**:3635-3646.
- 467 14. **Melgaco FG, Correa AA, Ganime AC, Brandao MLL, Medeiros VM,**  
468 **Rosas CO, Lopes S, Miagostovich MP.** 2018. Evaluation of skimmed milk  
469 flocculation method for virus recovery from tomatoes. *Brazilian journal of*  
470 *microbiology* : [publication of the Brazilian Society for Microbiology].
- 471 15. **Ettayebi K, Crawford SE, Murakami K, Broughman JR, Karandikar U,**  
472 **Tenge VR, Neill FH, Blutt SE, Zeng XL, Qu L, Kou B, Opekun AR, Burrin**  
473 **D, Graham DY, Ramani S, Atmar RL, Estes MK.** 2016. Replication of  
474 human noroviruses in stem cell-derived human enteroids. *Science*  
475 **353**:1387-1393.
- 476 16. **Forest KT, Filutowicz MS.** 2003. Remodeling of replication initiator  
477 proteins. *Nature structural biology* **10**:496-498.
- 478 17. **Eden JS, Tanaka MM, Boni MF, Rawlinson WD, White PA.** 2013.  
479 Recombination within the pandemic norovirus GII.4 lineage. *Journal of*  
480 *virology* **87**:6270-6282.
- 481 18. **Bok K, Abente EJ, Realpe-Quintero M, Mitra T, Sosnovtsev SV,**  
482 **Kapikian AZ, Green KY.** 2009. Evolutionary dynamics of GII.4  
483 noroviruses over a 34-year period. *Journal of virology* **83**:11890-11901.
- 484 19. **Hansman GS, Natori K, Oka T, Ogawa S, Tanaka K, Nagata N, Ushijima**  
485 **H, Takeda N, Katayama K.** 2005. Cross-reactivity among sapovirus  
486 recombinant capsid proteins. *Archives of virology* **150**:21-36.
- 487 20. **Hansman GS, Saito H, Shibata C, Ishizuka S, Oseto M, Oka T, Takeda N.**  
488 2007. Outbreak of gastroenteritis due to sapovirus. *Journal of clinical*  
489 *microbiology* **45**:1347-1349.


- 490 21. **Koromyslova AD, Hansman GS.** 2017. Nanobodies targeting norovirus  
491 capsid reveal functional epitopes and potential mechanisms of  
492 neutralization. *PLoS pathogens* **13**:e1006636.
- 493 22. **Kabsch W.** 2010. XDS. *Acta Cryst.* **D66**:125-132.
- 494 23. **Sedji MI, Varbanov M, Meo M, Colin M, Mathieu L, Bertrand I.** 2018.  
495 Quantification of human adenovirus and norovirus in river water in the  
496 north-east of France. *Environmental science and pollution research*  
497 *international*.
- 498 24. **Pyrkov TV, Chugunov AO, Krylov NA, Nolde DE, Efremov RG.** 2009.  
499 PLATINUM: a web tool for analysis of hydrophobic/hydrophilic  
500 organization of biomolecular complexes. *Bioinformatics* **25**:1201-1202.
- 501 25. **McCoy AJ G-KR, Adams PD, Winn MD, Storoni LC, Read RJ.** . 2007.  
502 Phaser crystallographic software. *Journal of Applied Crystallography*.  
503 **40**:658-674.
- 504 26. **Emsley P LB, Scott WG, Cowtan K.** 2010. Features and development of  
505 Coot. *Acta Crystallographica Section D: Biological Crystallography*.  
506 **66**:486-501.
- 507 27. **Koromyslova A, Tripathi S, Morozov V, Schrotten H, Hansman GS.**  
508 2017. Human norovirus inhibition by a human milk oligosaccharide.  
509 *Virology* **508**:81-89.
- 510 28. **Singh BK, Leuthold MM, Hansman GS.** 2015. Human noroviruses'  
511 fondness for histo-blood group antigens. *Journal of virology* **89**:2024-  
512 2040.




- 513 29. **Bertolotti-Ciarlet A, White LJ, Chen R, Prasad BV, Estes MK.** 2002.  
514 Structural requirements for the assembly of Norwalk virus-like particles.  
515 *Journal of virology* **76**:4044-4055.
- 516 30. **Koromyslova AD, Hansman GS.** 2015. Nanobody binding to a conserved  
517 epitope promotes norovirus particle disassembly. *Journal of virology*  
518 **89**:2718-2730.
- 519 31. **Parra GI, Bok K, Taylor R, Haynes JR, Sosnovtsev SV, Richardson C,**  
520 **Green KY.** 2012. Immunogenicity and specificity of norovirus Consensus  
521 GII.4 virus-like particles in monovalent and bivalent vaccine formulations.  
522 *Vaccine* **30**:3580-3586.
- 523 32. **Bernstein DI, Atmar RL, Lyon GM, Treanor JJ, Chen WH, Jiang X, Vinje**  
524 **J, Gregoricus N, Frenck RW, Jr., Moe CL, Al-Ibrahim MS, Barrett J,**  
525 **Ferreira J, Estes MK, Graham DY, Goodwin R, Borkowski A, Clemens**  
526 **R, Mendelman PM.** 2015. Norovirus vaccine against experimental human  
527 GII.4 virus illness: a challenge study in healthy adults. *The Journal of*  
528 *infectious diseases* **211**:870-878.
- 529 33. **Koromyslova A, Hansman GS.** 2017. Nanobodies targeting norovirus  
530 capsid reveal functional epitopes and potential mechanisms of  
531 neutralization. *PLoS pathogens* **In press**.
- 532 34. **Hansman GS, Doan LT, K Nguyen TA, Okitsu S, Katayama K, Ogawa S,**  
533 **Natori K, Takeda N, Kato Y, Nishio O, Noda M, Ushijima H.** 2004.  
534 Detection of norovirus and sapovirus infection among children with  
535 gastroenteritis in Ho Chi Minh City, Vietnam. *Archives of virology*  
536 **149**:1673-1688.
- 537




NSW-2012	1	MKMASSDANPSDGSAAANLVPEVNNEVMALEPVVGAATAAPVAGQQNVIDPWIRNNFVQAP	60
CHDC-1974	1	.....T.....I.....	60
GII.4c	1	.....T.....	60
		*****	
NSW-2012	61	GGEFTVSPRNAPGEILWSAPLGPLNPLYSHLARMYNGYAGGFVQVILAGNAFTAGKVI	120
CHDC-1974	61	.....S.....S.....I.....	120
GII.4c	61	.....I.....	120
		*****	
NSW-2012	121	FAAVPPNFPTEGLSPSQVTMFPHIIVVDVRQLEPVLIPDPVRNMFYHYNQSNPTIKLIA	180
CHDC-1974	121	...I.....I.....AH.S.L...	180
GII.4c	121	.....I.....	180
		*** *****	
NSW-2012	181	MLYTPLRANNAGDDVFTVSCRVLTRPSPDFDFIFLVPPTVESRTKPFVSVPLTVEEMTNS	240
CHDC-1974	181	.....T..I.....S..	240
GII.4c	181	.....T..I.....	240
		*****	
NSW-2012	241	RFPIPLEKLFTGPSSAFVVQPQNGRCTTDGVLGTTQLSPVNICTFRGDVTHITGSRNYT	300
CHDC-1974	241	.....Y.....A...N.....RVGI.HD..	300
GII.4c	241	.....G.....A.TQE..	300
		*****	
NSW-2012	301	MNLASQNWNVDYDPTEEIPAPLGTPDFVGKIQGVLQTTRTDGSTRGHKATVYTGSAFAP	360
CHDC-1974	301	...V....N.....L.....A....A....S...VH.T.	360
GII.4c	301	.....N.....G.....S...VH.T.	360
		*** *****	
NSW-2012	361	KLGRVQFETDTRDFEANQNTKFTPVGVIQDGGTTHRNEPQQWVLPSYSGRNTHNVHLAP	420
CHDC-1974	361	...S...T...NN..QTG.....DH-.Q.....N...TSG.....	419
GII.4c	361	...S...S...SN...TG.....V...S...Q.....D...DS.....	420
		*** ** * * ***** * * ***** * * *****	
		↑	
NSW-2012	421	AVAPTFPGEQLLFFRSTMPGCSGYPNMDLCLLPQEWWQYFYQEAAPAQSDVALLRFVNP	480
CHDC-1974	420	.....N.....SH.....	479
GII.4c	421	.....N.....H.....	480
		*****	
NSW-2012	481	DTGRVLFECKLHKSGYVTVAHGTQHDLVIPPNYFRFDSWVNQFYTLAPMNGTGRRRAV	540
CHDC-1974	480	.....I.....PY.....S...K.VL	539
GII.4c	481	.....L	540
		*****	




GII.4 NSW-2012



GII.4 CHDC-1974




GI.1 West Chester



GII.10 026-Vietnam

A



B




Figure 4




Figure 5







Figure 6






A




A/B dimer

C/D dimer



B



A/B dimer

C/D dimer






Figure 8



A



B




Figure 10








Figure 11






A




A/B dimer

C/D dimer



B



A/B dimer

C/D dimer




Figure 14






Figure 15

